cyclopenol: RN given refers to cis-(-)-isomer
ID Source | ID |
---|---|
PubMed CID | 101201 |
MeSH ID | M0129766 |
PubMed CID | 16681741 |
CHEMBL ID | 1602950 |
MeSH ID | M0129766 |
Synonym |
---|
cyclopenol |
3'-(3-hydroxyphenyl)-4-methylspiro[1h-1,4-benzodiazepine-3,2'-oxirane]-2,5-dione |
3'-(3-hydroxyphenyl)-4-methylspiro[1,4-benzodiazepine-3,2'-oxirane]-2,5(1h,4h)-dione |
spiro[3h-1,4-benzodiazepine-3,2'-oxirane]-2,5(1h,4h)-dione, 3'-(3-hydroxyphenyl)-4-methyl-, cis-(-)- |
BDDNYDPRCCDQQJ-UHFFFAOYSA-N |
cyclophenol |
J-012938 |
nsc-604990 |
20007-85-6 |
ACON1_000429 |
ACON0_000793 |
smr000440652 |
MLS000877017 , |
MEGXM0_000047 |
NCGC00169088-01 |
BRD-K36544484-001-01-3 |
nsc 604990 |
4q2498l80a , |
unii-4q2498l80a |
(-)-cyclopenol |
HMS2268I04 |
bdbm52763 |
(3s,3''r)-3''-(3-hydroxyphenyl)-4-methyl-spiro[1h-1,4-benzodiazepine-3,2''-oxirane]-2,5-quinone |
cid_16681741 |
(3s,3''r)-3''-(3-hydroxyphenyl)-4-methylspiro[1h-1,4-benzodiazepine-3,2''-oxirane]-2,5-dione |
(3s,3''r)-3''-(3-hydroxyphenyl)-4-methyl-spiro[1h-1,4-benzodiazepine-3,2''-oxirane]-2,5-dione |
CHEMBL1602950 |
cyclopenol, (-)- |
(2's,3'r)-3'-(3-hydroxyphenyl)-4-methylspiro(3h-1,4-benzodiazepine-3,2'-oxirane)-2,5(1h,4h)-dione |
spiro(3h-1,4-benzodiazepine-3,2'-oxirane)-2,5(1h,4h)-dione, 3'-(3-hydroxyphenyl)-4-methyl-, (2's,3'r)- |
cyclopenol, >=95% (lc/ms-elsd) |
NCGC00169088-03 |
(3s,3'r)-3'-(3-hydroxyphenyl)-4-methylspiro[1h-1,4-benzodiazepine-3,2'-oxirane]-2,5-dione |
(a?-cyclopenol |
Q27260352 |
(2's,3'r)-3'-(3-hydroxyphenyl)-4-methyl-spiro[3h-1,4-benzodiazepine-3,2'-oxirane]-2,5(1h,4h)-dione |
CS-0079523 |
HY-121133 |
AKOS040735413 |
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 35.4813 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 39.8107 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
GLS protein | Homo sapiens (human) | Potency | 17.7828 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 50.1187 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 79.4328 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.4125 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
DNA polymerase beta | Homo sapiens (human) | Potency | 44.6684 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 70.7946 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
tumor susceptibility gene 101 protein | Homo sapiens (human) | Potency | 50.1187 | 0.1298 | 10.8331 | 32.6090 | AID493005 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 24.5766 | 0.1000 | 28.9256 | 213.3130 | AID588591; AID720502 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 31.6228 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
Vpr | Human immunodeficiency virus 1 | Potency | 31.6228 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 35.4813 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 7.9433 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
POsterior Segregation | Caenorhabditis elegans | EC50 (µMol) | 4.1290 | 2.2010 | 47.1808 | 186.6810 | AID1964 |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | EC50 (µMol) | 35.0840 | 0.0820 | 31.0243 | 168.9080 | AID1960 |
Zinc finger protein mex-5 | Caenorhabditis elegans | EC50 (µMol) | 35.0840 | 0.0820 | 33.5679 | 168.9080 | AID1960 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Sodium-dependent noradrenaline transporter | Homo sapiens (human) |
cell surface | Sodium-dependent noradrenaline transporter | Homo sapiens (human) |
membrane | Sodium-dependent noradrenaline transporter | Homo sapiens (human) |
neuronal cell body membrane | Sodium-dependent noradrenaline transporter | Homo sapiens (human) |
presynaptic membrane | Sodium-dependent noradrenaline transporter | Homo sapiens (human) |
plasma membrane | Sodium-dependent noradrenaline transporter | Homo sapiens (human) |
axon | Sodium-dependent noradrenaline transporter | Homo sapiens (human) |
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (18.75) | 18.7374 |
1990's | 1 (6.25) | 18.2507 |
2000's | 2 (12.50) | 29.6817 |
2010's | 6 (37.50) | 24.3611 |
2020's | 4 (25.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.28) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |